Geriatric Assessment and Management (GAM) for Older Adults With Non-Small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy (GAM-CRT)
City of Hope Medical Center
Summary
This clinical trial tests how well a geriatric assessment (GA) with GA-directed treatment recommendations, compared to GA with usual care, works in identifying risk factors, reducing chemotherapy radiation toxicity and functional decline, and improving the overall quality of life in older patients with non-small cell lung cancer (NSCLC). Older patients with lung cancer undergoing chemotherapy are at an increased risk of adverse outcomes including treatment toxicity and functional and physical consequences. This makes it very challenging for the physicians to balance the benefits against the risk of chemotherapy in older cancer patients. A geriatric assessment may be useful in identifying risk factors for chemotherapy radiation toxicity. Communicating these geriatric assessment findings and assessment-based recommendations to a patient's treating physicians may help them make more informed decisions about treatment options for patients. Making treatment decisions using GA-based recommendations may reduce adverse events and improve outcomes in patients receiving treatment for NSCLC.
Description
PRIMARY OBJECTIVE: I. To demonstrate if providing a GA summary and recommendations for GA-directed interventions to oncology care teams decreases the proportion of older adults with unresectable, stage III NSCLC who experience any grade 3-5 non-hematologic toxicity from chemotherapy and radiation. SECONDARY OBJECTIVES: I. To demonstrate the differences between the intervention versus usual care group among: Ia. Overall grade 3-5 toxicities; Ib. Patient-reported symptomatic toxicities as measured by Patient Reported Outcomes - Common Terminology Criteria for Adverse Events (PROCTCAE), Patie…
Eligibility
- Age range
- 60+ years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * ONCOLOGY PHYSICIANS INCLUSION: * Oncology physicians must work at the participating site with no plans to leave that site or retire at the time of enrollment into the study * PATIENTS INCLUSION: * Any patient with unresectable non-small cell lung cancer diagnosis who is 60 years of age or older and must be treated at the participating site * Clinical staging without pathological confirmation of nodal disease is allowed * Plan to start a new cancer treatment regimen within 4-6 weeks from time of baseline study visit. The treatment regimen is up to the discretion of the tr…
Interventions
- OtherBest Practice
Receive usual care
- ProcedureBiospecimen Collection
Undergo blood and stool sample collection
- OtherCommunication Intervention
Receive GA assessment summary and assessment-based recommendations
- OtherComprehensive Geriatric Assessment
Complete GA
- OtherElectronic Health Record Review
Ancillary studies
- OtherSurvey Administration
Ancillary studies
Locations (3)
- City of Hope Medical CenterDuarte, California
- University of RochesterRochester, New York
- Ohio State University Comprehensive Cancer CenterColumbus, Ohio